Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Veracyte, Inc., known simply as Veracyte, is a prominent global genomic diagnostics company headquartered in the United States. Established in 2008, Veracyte is dedicated to revolutionising cancer care by providing early and accurate genomic insights to patients and clinicians worldwide.
The company develops and commercialises a comprehensive portfolio of advanced genomic tests, including solutions like Afirma®, Percepta®, and Prosigna®. These innovative diagnostic tools offer less invasive pathways for disease diagnosis and guide treatment decisions, optimising patient outcomes in oncology.
Having delivered over 1.5 million tests globally, Veracyte has solidified its position as a trusted leader in precision medicine. Its pioneering genomic science and expanding international presence underscore its commitment to transforming the standard of cancer diagnosis and treatment.
-11 vs industry average
Veracyte’s score of 31 is lower than 43% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
No reported emissions data is available for Veracyte yet.
Veracyte, Inc., a US-headquartered pharmaceutical preparation manufacturing company, has committed to significant climate action. The company has established near-term Science Based Targets initiative (SBTi) commitments to reduce its carbon footprint. Veracyte pledges to reduce absolute Scope 1 and 2 greenhouse gas (GHG) emissions by 42.0% by 2030, using a 2024 base year. Additionally, the company is committed to reducing absolute Scope 3 GHG emissions by 25.0% within the same timeframe. This Scope 3 target specifically addresses emissions from purchased goods and services, fuel- and energy-related activities, upstream transportation and distribution, business travel, and employee commuting. These commitments align with the reductions required to keep global warming to 1.5°C.
2030
42% reduction in Scope 1
Veracyte, Inc. commits to reduce absolute scope 1 and 2 GHG emissions 42.0% by 2030 from a 2024 base year
2030
25% reduction in scope 3 upstream
Veracyte, Inc. also commits to reduce absolute scope 3 GHG emissions from purchased goods and services, fuel- and energy-related activities,…
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
No scope 3 category breakdown has been disclosed yet.


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more